Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 159,588 275,693 319,053 656,089
Total Sell Value $13,270,852 $23,760,160 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 10 21 27 56
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 2582
  Page 23 of 104  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2019-03-15 4 D $94.53 $2,660,358 D/D (28,143) 300,558     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2019-03-15 4 A $0.00 $0 D/D 9,370 64,681     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2019-03-15 4 D $94.53 $683,168 D/D (7,227) 55,311     -
   Baffi Robert EVP, Technical Operations   •       –      –    2019-03-15 4 A $0.00 $0 D/D 9,630 96,759     -
   Baffi Robert EVP, Technical Operations   •       –      –    2019-03-15 4 D $94.53 $669,556 D/D (7,083) 87,129     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2019-03-15 4 A $0.00 $0 D/D 12,840 145,901     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2019-03-15 4 D $94.53 $892,647 D/D (9,443) 133,061     -
   Davis George Eric EVP, General Counsel   •       –      –    2019-03-15 4 A $0.00 $0 D/D 9,370 86,469     -
   Davis George Eric EVP, General Counsel   •       –      –    2019-03-15 4 D $94.53 $628,435 D/D (6,648) 77,099     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2019-03-13 4 AS $93.42 $280,253 D/D (3,000) 328,701     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2019-03-13 4 OE $14.39 $43,170 D/D 3,000 331,701     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2019-03-12 4 AS $91.44 $365,770 D/D (4,000) 328,701     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2019-03-12 4 OE $14.39 $57,560 D/D 4,000 332,701     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2019-03-11 4 AS $88.96 $444,780 D/D (5,000) 328,701     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2019-03-11 4 OE $14.39 $71,950 D/D 5,000 333,701     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2019-03-07 4 AS $90.78 $363,120 D/D (4,000) 328,701     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2019-03-07 4 OE $14.39 $57,560 D/D 4,000 332,701     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2019-03-04 4 AS $95.00 $208,620 D/D (2,196) 142,504     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2019-03-01 4 D $94.76 $86,421 D/D (912) 62,538     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2019-03-01 4 A $0.00 $0 D/D 12,205 63,450     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2019-03-01 4 D $94.76 $465,177 D/D (4,909) 328,701     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2019-03-01 4 A $0.00 $0 D/D 45,320 333,610     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2019-03-01 4 D $94.76 $86,895 D/D (917) 60,775     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2019-03-01 4 A $0.00 $0 D/D 12,557 61,692     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2019-03-01 4 D $94.76 $109,353 D/D (1,154) 144,700     -
  2582 Records found
  Previous  20  21  22  23  24  25  26  27  28  29  Next   
  Page 23 of 104
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us